

WHAT IS CLAIMED IS:

- 1 **1.** A liposomal formulation comprising:
 - 2 a) L-carnitine; and
 - 3 b) a liposome.
- 1 **2.** The formulation of claim 1, wherein said L-carnitine is propionyl-L-
2 carnitine.
- 1 **3.** The formulation of claim 1, wherein said L-carnitine is acetyl-L-
2 carnitine.
- 1 **4.** The formulation of claim 1, wherein said liposome is an Optisome™.
- 1 **5.** The formulation of claim 1, wherein said L-carnitine is encapsulated in
2 said liposome.
- 1 **6.** A liposomal formulation comprising:
 - 2 a) an L-carnitine derivative; and
 - 3 b) a liposome.
- 1 **7.** The formulation of claim 6, wherein said L-carnitine is alkyl-L-
2 carnitine ester.
- 1 **8.** A method for treating a peripheral arterial disease in a mammal, said
2 method comprising:
 - 3 administering a therapeutically effective amount of a liposomal formulation of
4 L-carnitine, thereby treating a peripheral arterial disease in said mammal.
- 1 **9.** The method according to claim 8, wherein said mammal is a human
2 being.
- 1 **10.** The method according to claim 8, wherein said disease or symptom is
2 intermittent claudication.
- 1 **11.** The method according to claim 8, wherein said L-carnitine is propionyl
2 L-carnitine.